Skip to main content

Cardio Diagnostics Holdings, Inc.

For the period ended Dec 31, 2025. Filed Mar 13, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 13, 2026

CDIO$1.82+10.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Power of Attorney

Each person whose signature appears below constitutes and appoints Meeshanthini V. Dogan and Elisa Luqman, and each one of them, as her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for her and in their name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitle and CapacityDate
/s/ Meeshanthini V. DoganChief Executive Officer and DirectorMarch 13, 2026
Meeshanthini V. Dogan, PhD
/s/ Elisa LuqmanChief Financial Officer and PrincipalMarch 13, 2026
Elisa LuqmanAccounting Officer
/s/ Warren HosseinionDirector (Chairman of the Board)March 13, 2026
Warren Hosseinion, MD
/s/ James IntraterDirectorMarch 13, 2026
James Intrater
/s/ Peter K. FungDirectorMarch 13, 2026
Peter K. Fung
/s/ Wendy J. BettsDirectorMarch 13, 2026
Wendy J. Betts
/s/ Robert PhilibertDirectorMarch 13, 2026
Robert Philibert, MD
/s/ Paul BurtonDirectorMarch 13, 2026
Paul Burton
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.